ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 171 filers reported holding ASCENDIS PHARMA A/S in Q2 2022. The put-call ratio across all filers is 0.47 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $319,593 | +9423.0% | 3,413 | -87.6% | 0.00% | -95.5% |
| Q4 2022 | $3,356 | -99.9% | 27,476 | -14.0% | 0.07% | -7.0% |
| Q3 2022 | $3,297,000 | +70.4% | 31,932 | +53.4% | 0.07% | +39.2% |
| Q2 2022 | $1,935,000 | +72.9% | 20,814 | +144.6% | 0.05% | +142.9% |
| Q2 2021 | $1,119,000 | -54.0% | 8,509 | -54.9% | 0.02% | -57.1% |
| Q1 2021 | $2,431,000 | +13.2% | 18,862 | +46.5% | 0.05% | -19.7% |
| Q4 2020 | $2,147,000 | +196.1% | 12,872 | +173.9% | 0.06% | +90.6% |
| Q3 2020 | $725,000 | +56.9% | 4,700 | +50.4% | 0.03% | +39.1% |
| Q2 2020 | $462,000 | -39.7% | 3,125 | -73.3% | 0.02% | -8.0% |
| Q1 2018 | $766,000 | +154.5% | 11,705 | +55.9% | 0.02% | +212.5% |
| Q4 2017 | $301,000 | +40.0% | 7,510 | +26.9% | 0.01% | +60.0% |
| Q3 2017 | $215,000 | – | 5,918 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 11,225,357 | $1,001,863,112 | 18.92% |
| Q Global Advisors, LLC | 195,000 | $17,404 | 12.55% |
| Sofinnova Investments, Inc. | 754,032 | $67,297,356 | 4.41% |
| Avoro Capital Advisors LLC | 3,580,555 | $319,564,534 | 4.34% |
| Finepoint Capital LP | 139,772 | $12,474,651 | 4.32% |
| Spyglass Capital Management LLC | 657,853 | $58,713,380 | 4.24% |
| Saturn V Capital Management LP | 78,442 | $7,000,948 | 3.88% |
| DAFNA Capital Management LLC | 135,212 | $12,067,671 | 3.30% |
| ARS Investment Partners, LLC | 289,860 | $25,870,005 | 3.02% |
| Ghost Tree Capital, LLC | 100,000 | $8,925,000 | 2.95% |